

Akers Biosciences Inc  
Form 8-K  
November 07, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 4, 2014**

**AKERS BIOSCIENCES INC.**

(Exact name of registrant as specified in its charter)

**New Jersey**

(State or other jurisdiction  
of incorporation)

**333-190456**

(Commission File Number)

**22-2983783**

(IRS Employer  
Identification No.)

**201 Grove Road**

**Thorofare, NJ 08086**

(Address of Principal Executive Offices)

**(856) 848-2116**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 4, 2014, the Company held its 2014 annual meeting of stockholders (the “Annual Meeting”). Greater than 40% of the shares of common stock outstanding and entitled to vote at the Annual Meeting were present in person or by proxy thereby constituting a quorum in accordance with the Company’s by-laws.

The matters that were voted upon at the Annual Meeting, and the number of votes cast for or against/withheld, as well as the number of abstentions and broker non-votes, as to such matters, where applicable, are set forth in the table below. With respect to the election of Raymond F. Akers, Jr., Ph.D, Thomas Knox, Brandon Knox, and Gavin Moran as directors to each serve a one-year term on the Board and until each of their successors is elected and qualified, each nominee received the number of votes set forth opposite his name.

	Number of Votes		Abstentions	Broker Non-Votes
	Votes For	Votes Against/Withheld		
Election of Raymond F. Akers, Jr. Ph.D	1,601,591	0	48,269	-
Election of Thomas Knox	1,603,366	0	46,494	-
Election of Brandon Knox	1,264,932	0	384,928	-
Election of Gavin Moran	1,522,249	0	127,611	-
Ratification of MorisonCogen, LP, the Company's independent registered public accountant, to audit the Company's consolidated financial statements for 2014	2,617,499	0	3,275	-
Non-binding advisory vote on the Company's Executive Compensation	1,172,001	15,367	462,492	-

	1 Year	2 Years	3 Years	Abstentions
Non-binding advisory vote to approve the frequency of advisory votes on executive compensation	539,735	640,074	381,195	88,792

On the basis of the above votes, (i) Raymond F. Akers, Jr., Ph.D, Thomas Knox, Brandon Knox, and Gavin Moran were elected as members of the Board and (ii) the proposal to ratify the selection of MorisonCogen, LP, as the Company’s independent registered public accountant to audit its consolidated financial statements for 2014 was adopted. The stockholders also voted a sufficient number of non-binding advisory votes to approve (iii) the Company’s executive compensation and (iv) the two-year frequency for advisory votes on executive compensation.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AKERS BIOSCIENCES, INC.**

Date: November 7, 2014 By: */s/ Raymond F. Akers, Jr., Ph.D*  
Raymond F. Akers, Jr., Ph.D  
Executive Chairman